VRDN Similar Chart Price Prediction
The price of VRDN is predicted to go up -27.42%, based on the high correlation periods with CYBN. The similarity of these two price pattern on the periods is 98.41%.
VRDN
CYBN
Down: -27.42%Similarity: 98.41%
VRDN Revenue Forecast
VRDN EPS Forecast
VRDN FAQs
What is VRDN revenue forecast for next quarter？
What is VRDN eps forecast for next quarter？
VRDN Analyst's Forecast
Derek Archila
Wells Fargo
Buy → Hold
2024-12-19
Price Target
$27
Upside
+44.15%
Wells Fargo downgraded Viridian Therapeutics to Equal Weight from Overweight with a price target of $27, down from $37. The firm says its thesis on veligrotug played out in thyroid eye disease, and that the drug will get approved and be successful commercially. That said, the approval won't be until the second half of 2026 along with VRDN-003's Phase 3 data, Viridian's key value driver, the analyst tells investors in a research note. It cites a lack of catalysts for the downgrade.
Gregory Renza
RBC Capital
Buy
2024-12-17
Price Target
$44 → $47
Upside
+125.74%
Joseph Thome
TD Cowen
Strong Buy
2024-11-25
Price Target
n/a
Downside
0%
